Mathew N T, Kailasam J, Gentry P, Chernyshev O
Houston, Headache Clinic, TX 77004, USA.
Headache. 2000 Jun;40(6):464-5. doi: 10.1046/j.1526-4610.2000.00069.x.
In order to study the effect of zolmitriptan and rizatriptan in oral sumatriptan nonresponders (defined as lack of response in three or more of five attacks), 56 patients were studied in an open trial in a crossover fashion. Both zolmitriptan, 5 mg, and rizatriptan, 10 mg, were effective in the majority of sumatriptan nonresponders. The response to rizatriptan, 10 mg, appeared to be better than to zolmitriptan, 5 mg. Approximately 19% of sumatriptan nonresponders remained nonresponders to both zolmitriptan and rizatriptan.
为研究佐米曲普坦和利扎曲普坦对口服舒马曲坦无效者（定义为在五次发作中三次或更多次发作无反应）的疗效，以交叉方式对56例患者进行了开放试验研究。5毫克佐米曲普坦和10毫克利扎曲普坦对大多数舒马曲坦无效者均有效。10毫克利扎曲普坦的疗效似乎优于5毫克佐米曲普坦。约19%的舒马曲坦无效者对佐米曲普坦和利扎曲普坦均无反应。
